Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Solutions Reports Disappointing Revenue, Widened Loss in Q4

NEW YORK, Feb. 14 - Genomic Solutions on Thursday posted slumping revenue atop a wider loss following its acquisition of Cartesian Technologies.

 

Revenue for the period ended Dec. 31 was $4.4 million compared with $5.5 million one year ago, results that the company said had missed expectations.

 

R&D spending in the quarter also fell, to $1.4 million from $1.5 million last year while restructuring costs, pegged at $8.6 million, made up the brunt of Genomic Solutions' expenses for the quarter.

 

As a result, net loss was $12.3 million, or $.49 per share, for the fourth quarter 2001 compared with $1.3 million, or $.05, year over year. Genomic Solutions had $13.1 million in the bank at the end of the quarter.

 

"While 2001 did not meet our financial expectations, we made significant strides toward profitability and implementation of our business plan with our cost reduction initiatives and our acquisition of Cartesian Technologies," which closed on Dec. 18, said Jeffrey Williams, president and CEO of Genomic Solutions.

 

Looking ahead, the company said that revenue "will exceed $30 million." Total revenue in fiscal 2001 was $17 million, which well from $19 million in 2000.

The Scan

Alzheimer's Risk Gene Among Women

CNN reports that researchers have found that variants in MGMT contribute to Alzheimer's disease risk among women but not men.

Still Hanging Around

The Guardian writes that persistent pockets of SARS-CoV-2 in the body could contribute to long COVID.

Through a Little Spit

Enteric viruses like norovirus may also be transmitted through saliva, not just the fecal-oral route, according to New Scientist.

Nature Papers Present Method to Detect Full Transcriptome, Viruses Infecting Asgard Archaea, More

In Nature this week: VASA-seq approach to detect full transcriptome, analysis of viruses infecting Asgard archaea, and more.